Drug Discovery World
MAY 1, 2024
DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Artificial intelligence (AI) AI is on everyone’s minds as we head into 2024; of course, this is across not just the drug discovery spectrum but is particularly relevant to therapeutic antibodies.
Drug Discovery World
FEBRUARY 8, 2024
In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. DDW Volume 25 – Issue 1, Winter 2023/2024 The post Guide to using AAV vectors in gene therapy appeared first on Drug Discovery World (DDW). How is the titer determined?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Broad Institute
APRIL 25, 2024
By Allessandra DiCorato April 25, 2024 As night fell on July 20th, 2014, genomicist Christian Happi was at home with his family in Lagos, Nigeria when he received a phone call he would never forget. Since 2007, they’d been studying Lassa fever, an often deadly illness caused by infection with the Lassa virus, which is endemic in West Africa.
Alta Sciences
MARCH 1, 2024
Q&A With Dr. Norbert Makori and Pierre Jolicoeur: The Benefits of Combining Preclinical and Bioanalytical for Your Gene Therapy Studies pmjackson Fri, 03/01/2024 - 22:20 Recent advances in gene therapy have allowed for diseases to be approached differently. We have a supply of NHPs to ensure prompt study start.
Broad Institute
MAY 14, 2024
William Studier for development of widely used protein- and RNA-production platform By Corie Lok May 14, 2024 Breadcrumb Home Merkin Prize in Biomedical Technology awarded to F. By Broad Communications May 14, 2024 F. Studier will be honored in a prize ceremony held on September 17, 2024. Photo courtesy of BNL.
Drug Discovery World
APRIL 30, 2024
This novel approach allows for the modulation of mRNA biology to either increase or decrease protein production, offering the versatility to target a wide range of mechanisms of action (MOA),” Slonim states. At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed.
Broad Institute
JANUARY 30, 2024
He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.
Expert insights. Personalized for you.
147 
Let's personalize your content